warfarin

Summary

Summary: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Top Publications

  1. ncbi Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation
    Morten L Hansen
    Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 2900, Hellerup, Copenhagen, Denmark
    Arch Intern Med 170:1433-41. 2010
  2. ncbi Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 365:883-91. 2011
  3. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
  4. ncbi Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
  5. ncbi Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    Robert G Hart
    Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Ann Intern Med 146:857-67. 2007
  6. ncbi Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    N Engl J Med 368:709-18. 2013
  7. ncbi Edoxaban versus warfarin in patients with atrial fibrillation
    Robert P Giugliano
    From Brigham and Women s Hospital and Harvard Medical School, Boston R P G, C T R, E B, S A M, S D W, L T G, E M A Mount Sinai Medical Center, New York J L H University Hospitals Case Medical Center, Cleveland A L W Thomas Jefferson Medical College, Philadelphia M D E McMaster University, Hamilton, ON, Canada J I W University Hospital, Jihlavská, Brno, Czech Republic J S Institute of Cardiology, Warsaw, Poland W R Cardiology Research Center, Moscow M R National Hospital Organization, Osaka National Hospital, Osaka, Japan Y K Quintiles, Durham, NC J B, S P P and Daiichi Sankyo Pharma Development, Edison, NJ M S, I P, J J H, M M
    N Engl J Med 369:2093-104. 2013
  8. pmc The net clinical benefit of warfarin anticoagulation in atrial fibrillation
    Daniel E Singer
    Massachusetts General Hospital, Boston, Massachussetts 02114, USA
    Ann Intern Med 151:297-305. 2009
  9. ncbi Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Daniel E Singer
    Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Chest 133:546S-592S. 2008
  10. ncbi Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
    Jonathan Mant
    Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
    Lancet 370:493-503. 2007

Detail Information

Publications365 found, 100 shown here

  1. ncbi Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation
    Morten L Hansen
    Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 2900, Hellerup, Copenhagen, Denmark
    Arch Intern Med 170:1433-41. 2010
    ..Patients with atrial fibrillation (AF) often require anticoagulation and platelet inhibition, but data are limited on the bleeding risk of combination therapy...
  2. ncbi Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 365:883-91. 2011
    The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment...
  3. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    b>Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.
  4. ncbi Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
    ..Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin...
  5. ncbi Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    Robert G Hart
    Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Ann Intern Med 146:857-67. 2007
    ..Atrial fibrillation is a strong independent risk factor for stroke...
  6. ncbi Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    N Engl J Med 368:709-18. 2013
    ..Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism...
  7. ncbi Edoxaban versus warfarin in patients with atrial fibrillation
    Robert P Giugliano
    From Brigham and Women s Hospital and Harvard Medical School, Boston R P G, C T R, E B, S A M, S D W, L T G, E M A Mount Sinai Medical Center, New York J L H University Hospitals Case Medical Center, Cleveland A L W Thomas Jefferson Medical College, Philadelphia M D E McMaster University, Hamilton, ON, Canada J I W University Hospital, Jihlavská, Brno, Czech Republic J S Institute of Cardiology, Warsaw, Poland W R Cardiology Research Center, Moscow M R National Hospital Organization, Osaka National Hospital, Osaka, Japan Y K Quintiles, Durham, NC J B, S P P and Daiichi Sankyo Pharma Development, Edison, NJ M S, I P, J J H, M M
    N Engl J Med 369:2093-104. 2013
    Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.
  8. pmc The net clinical benefit of warfarin anticoagulation in atrial fibrillation
    Daniel E Singer
    Massachusetts General Hospital, Boston, Massachussetts 02114, USA
    Ann Intern Med 151:297-305. 2009
    Guidelines recommend warfarin use in patients with atrial fibrillation solely on the basis of risk for ischemic stroke without antithrombotic therapy...
  9. ncbi Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Daniel E Singer
    Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Chest 133:546S-592S. 2008
    ..ischemic attack (TIA), or systemic embolism, we recommend long-term anticoagulation with an oral VKA, such as warfarin, because of the high risk of future ischemic stroke faced by this set of patients (Grade 1A)...
  10. ncbi Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
    Jonathan Mant
    Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
    Lancet 370:493-503. 2007
    ..We assessed whether warfarin reduced risk of major stroke, arterial embolism, or other intracranial haemorrhage compared with aspirin in ..
  11. ncbi Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    John W Eikelboom
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
    Circulation 123:2363-72. 2011
    Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation...
  12. ncbi Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
    The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism.
  13. ncbi A randomized trial of genotype-guided dosing of warfarin
    Munir Pirmohamed
    From the University of Liverpool M P, G B, A L J, C H T, J E Z, P R W and Royal Liverpool and Broadgreen University Hospital National Health Service NHS Trust M P, C H T, Liverpool, Whiston Hospital, Prescot T N, and Newcastle upon Tyne NHS Trust P K and Newcastle University J B L, A K D, P A, F K, Newcastle upon Tyne all in the United Kingdom Uppsala University, Department of Medical Sciences N E, C C, H K, M W, Uppsala Clinical Research Center N E and Uppsala University Hospital C C, B W, M W, Uppsala, and Enköping Hospital, Enköping C S all in Sweden and Utrecht University, Utrecht, the Netherlands A H M Z
    N Engl J Med 369:2294-303. 2013
    The level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict during the initiation of therapy...
  14. ncbi Identification of the gene for vitamin K epoxide reductase
    Tao Li
    Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Nature 427:541-4. 2004
    Vitamin K epoxide reductase (VKOR) is the target of warfarin, the most widely prescribed anticoagulant for thromboembolic disorders...
  15. ncbi Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala University, Dag Hammarskjolds vag 14B, Uppsala, Sweden
    Circulation 127:2166-76. 2013
    ..in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality...
  16. ncbi Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation
    Soyon Lee
    University of Connecticut School of Pharmacy, Storrs, CT, USA
    Am J Cardiol 110:845-51. 2012
    Rivaroxaban has been found to be noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage...
  17. ncbi Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial
    Robert G Hart
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
    Stroke 43:1511-7. 2012
    Intracranial hemorrhage is the most devastating complication of anticoagulation. Outcomes associated with different sites of intracranial bleeding occurring with warfarin versus dabigatran have not been defined.
  18. pmc Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
    J A Johnson
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
    Clin Pharmacol Ther 90:625-9. 2011
    b>Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation...
  19. ncbi Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:975-83. 2010
    Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of 2·0-3·0...
  20. ncbi Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry
    Dhanunjaya Lakkireddy
    Division of Cardiovascular Diseases, Cardiovascular Research Institute, Mid America Cardiology, University of Kansas Hospital and Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160 7200, USA
    J Am Coll Cardiol 59:1168-74. 2012
    ..The purpose of this study was to evaluate the feasibility and safety of periprocedural dabigatran during atrial fibrillation (AF) ablation...
  21. pmc Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record
    Andrea H Ramirez
    Department of Medicine, Vanderbilt University in Nashville, TN 37232, USA
    Pharmacogenomics 13:407-18. 2012
    b>Warfarin pharmacogenomic algorithms reduce dosing error, but perform poorly in non-European-Americans...
  22. ncbi Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation
    Elaine M Hylek
    Research Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, 91 East Concord St, Suite 200, Boston, MA 02118, USA
    Circulation 115:2689-96. 2007
    b>Warfarin is effective in the prevention of stroke in atrial fibrillation but is under used in clinical care. Concerns exist that published rates of hemorrhage may not reflect real-world practice...
  23. ncbi Systematic overview of warfarin and its drug and food interactions
    Anne M Holbrook
    Centre for Evaluation of Medicines, St Joseph s Healthcare, Hamilton, Ontario
    Arch Intern Med 165:1095-106. 2005
    b>Warfarin is a highly efficacious oral anticoagulant, but its use is limited by a well-founded fear of bleeding. Drug and food interactions are frequently cited as causes of adverse events with warfarin...
  24. pmc Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
    Hooman Kamel
    Department of Neurology and Neuroscience, Weill Cornell Medical College, USA
    Neurology 79:1428-34. 2012
    To compare the cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in patients with atrial fibrillation (AF).
  25. pmc A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis
    Imre Noth
    University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637 6076, USA
    Am J Respir Crit Care Med 186:88-95. 2012
    ..Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis...
  26. pmc A pharmacogenetic versus a clinical algorithm for warfarin dosing
    Stephen E Kimmel
    The authors affiliations are listed in the Appendix
    N Engl J Med 369:2283-93. 2013
    The clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results.
  27. ncbi Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system
    Theodore Darkow
    Health Informatics and Outcomes Research Division, Prescription Solutions, Costa Mesa, CA 92626, USA
    Curr Med Res Opin 21:1583-94. 2005
    To examine warfarin utilization and clinical effectiveness among patients with nonvalvular atrial fibrillation within usual clinical care in a managed care system...
  28. ncbi Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion
    Rangadham Nagarakanti
    Louisiana State University School of Medicine, New Orleans, LA, USA
    Circulation 123:131-6. 2011
    The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran 110 mg BID (D110) and 150 mg BID (D150) with warfarin for stroke prevention in 18 113 patients with nonvalvular atrial fibrillation.
  29. ncbi Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial
    Stefan H Hohnloser
    Division of Clinical Electrophysiology, J W Goethe University Hospital, Theodor Stern Kai 7, Frankfurt, Germany
    Circulation 125:669-76. 2012
    ..There is a modest risk of myocardial infarction (MI) and myocardial ischemic events in patients with atrial fibrillation...
  30. ncbi Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am Heart J 157:805-10, 810.e1-2. 2009
    ..It is administered in a fixed dose without laboratory monitoring and is being compared with warfarin (international normalized ratio 2-3) in the RE-LY trial...
  31. ncbi Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study
    A S Go
    Kaiser Permanente Medical Care Program Northern California, Oakland 94611 5714, USA
    Ann Intern Med 131:927-34. 1999
    b>Warfarin dramatically reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not been widely studied.
  32. ncbi Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, Intermountain Healthcare, Salt Lake City, UT, USA
    Circulation 116:2563-70. 2007
    Pharmacogenetic-guided dosing of warfarin is a promising application of "personalized medicine" but has not been adequately tested in randomized trials.
  33. ncbi Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
    Shimoli V Shah
    Department of Medicine, Washington University School of Medicine, Campus Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    Circulation 123:2562-70. 2011
    Recent studies have investigated alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost-effective is unknown.
  34. pmc Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    B F Gage
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 84:326-31. 2008
    Initiation of warfarin therapy using trial-and-error dosing is problematic. Our goal was to develop and validate a pharmacogenetic algorithm...
  35. ncbi Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation
    Elaine M Hylek
    General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    N Engl J Med 349:1019-26. 2003
    ..0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation-related stroke is not known but is central to the choice of the target INR...
  36. pmc Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
    Nita A Limdi
    University of Alabama at Birmingham, USA
    Blood 115:3827-34. 2010
    b>Warfarin-dosing algorithms incorporating CYP2C9 and VKORC1 -1639G>A improve dose prediction compared with algorithms based solely on clinical and demographic factors...
  37. ncbi Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial
    Gregory W Albers
    Stanford Stroke Center, Palo Alto, Calif, USA
    JAMA 293:690-8. 2005
    In patients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use.
  38. ncbi Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
    Antonio L Dans
    College of Medicine, University of the Philippines Manila, Ermita, Manila, Philippines 1000
    Circulation 127:634-40. 2013
    ..showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 mg BID was noninferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation...
  39. ncbi An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
    Simon Mantha
    Department of Hematology, Lahey Clinic, Burlington, MA 01805, USA
    Thromb Haemost 108:476-84. 2012
    New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation...
  40. ncbi Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial
    Jeff S Healey
    Population Health Research Institute, McMaster University, Hamilton, Canada
    Circulation 126:343-8. 2012
    Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required.
  41. ncbi Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –
    Masatsugu Hori
    Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
    Circ J 76:2104-11. 2012
    The global ROCKET AF study evaluated once-daily rivaroxaban vs. warfarin for stroke and systemic embolism prevention in patients with atrial fibrillation (AF)...
  42. ncbi Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
    Edith Nutescu
    Department of Pharmacy Practice and Center for Pharmacoeconomic Research, University of Illinois at Chicago, College of Pharmacy, 833 S Wood St MC 886, Rm 164, Chicago, IL 60612, USA
    J Thromb Thrombolysis 31:326-43. 2011
    ..Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have been developed to address many of the shortcomings of warfarin therapy...
  43. ncbi A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)
    Jeffrey L Anderson
    Intermountain Medical Center, Cardiovascular Department, Murray, UT 84107 5701, USA
    Circulation 125:1997-2005. 2012
    b>Warfarin is characterized by marked variations in individual dose requirements and a narrow therapeutic window. Pharmacogenetics (PG) could improve dosing efficiency and safety, but clinical trials evidence is meager.
  44. ncbi Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
    Christian T Ruff
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA Electronic address
    Lancet 383:955-62. 2014
    Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition...
  45. pmc A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose
    Fumihiko Takeuchi
    Wellcome Trust Sanger Institute, Hinxton, UK
    PLoS Genet 5:e1000433. 2009
    ..5 x 10(-7)) for polymorphisms that modestly alter therapeutic warfarin dose...
  46. ncbi Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada S Schulman, C K Department of Hematology, Karolinska University Hospital, Stockholm, Sweden S S Thrombosis Research Institute and University College London, London, UK A K K Brigham and Women s Hospital, Harvard Medical School, Boston, MA S Z G Medical Division 2, Municipal Hospital Friedrichstadt, Dresden, Germany S Schellong Department of Medicine, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden H E Department of Vascular Pathology, Bellevue Hospital, Saint Etienne, France P M Clinical Research, Boehringer Ingelheim, Copenhagen, Denmark A V C Boehringer Ingelheim, Ridgefield, CT J F Boehringer Ingelheim, Reims, France F L M and Boehringer Ingelheim, Biberach and der Riss, BDM, Germany N P
    Circulation 129:764-72. 2014
    Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings.
  47. ncbi Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control
    Christopher Ll Morgan
    Cardiff Research Consortium Ltd, University Hospital of Wales, Heath Park, Cardiff CF14 4UJ, UK
    Thromb Res 124:37-41. 2009
    ..We aimed to determine the level of INR control associated with reduced stroke and mortality...
  48. pmc Warfarin discontinuation after starting warfarin for atrial fibrillation
    Margaret C Fang
    Department of Medicine, University of California, San Francisco, 94143, USA
    Circ Cardiovasc Qual Outcomes 3:624-31. 2010
    Although warfarin is widely recommended to prevent atrial fibrillation-related thromboembolism, many eligible patients do not take warfarin...
  49. pmc CYP4F2 genetic variant alters required warfarin dose
    Michael D Caldwell
    Department of Surgery, Marshfield Clinic, Marshfield, WI, USA
    Blood 111:4106-12. 2008
    b>Warfarin is an effective, commonly prescribed anticoagulant used to treat and prevent thrombotic events. Because of historically high rates of drug-associated adverse events, warfarin remains underprescribed...
  50. ncbi Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack
    Hooman Kamel
    Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY, USA
    Stroke 43:881-3. 2012
    ..The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed...
  51. ncbi Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infar
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 160:635-41. 2010
    ..Edoxaban is a selective and direct factor Xa inhibitor that may provide effective, safe, and more convenient anticoagulation...
  52. ncbi Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial
    Jonas Oldgren
    Uppsala Clinical Research Centre and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Ann Intern Med 155:660-7, W204. 2011
    ..There are sparse data on the risk for thrombotic and bleeding complications according to the CHADS(2) score in patients receiving anticoagulant therapy...
  53. ncbi Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis
    Shikhar Agarwal
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Ohio, USA
    Arch Intern Med 172:623-31; discussion 631-3. 2012
    ..prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide...
  54. pmc A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
    Margaret C Fang
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    J Am Coll Cardiol 58:395-401. 2011
    The purpose of this study was to develop a risk stratification score to predict warfarin-associated hemorrhage.
  55. ncbi The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage
    Jonathan Rosand
    Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114, USA
    Arch Intern Med 164:880-4. 2004
    b>Warfarin sodium is highly effective for prevention of embolic stroke, particularly in nonvalvular atrial fibrillation, but its expected benefit can be offset by risk of intracerebral hemorrhage (ICH)...
  56. ncbi Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis
    Marc I Chimowitz
    Department of Neurology, School of Medicine, Emory University, Atlanta, USA
    N Engl J Med 352:1305-16. 2005
    Atherosclerotic intracranial arterial stenosis is an important cause of stroke. Warfarin is commonly used in preference to aspirin for this disorder, but these therapies have not been compared in a randomized trial.
  57. ncbi Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation
    Corey S Miller
    Division of Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Am J Cardiol 110:453-60. 2012
    New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients with atrial fibrillation (AF)...
  58. ncbi Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
    Alan S Go
    Division of Research, Kaiser Permanente of Northern California, Oakland, CA 94612, USA
    JAMA 290:2685-92. 2003
    b>Warfarin has been shown to be highly efficacious for preventing thromboembolism in atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is less clear.
  59. pmc Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
    Joshua Pink
    Centre for Health Economics and Medicines Evaluation, Institute of Medical and Social Care Research, Bangor University, Bangor, Gwynedd LL57 1UT, UK
    BMJ 343:d6333. 2011
    To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United ..
  60. ncbi Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
    Hans Christoph Diener
    Department of Neurology, University Hospital Essen, Essen, Germany
    Lancet Neurol 9:1157-63. 2010
    ..Anticoagulation Therapy (RE-LY) trial, dabigatran reduced occurrence of both stroke and haemorrhage compared with warfarin in patients who had atrial fibrillation and were at increased risk of stroke...
  61. ncbi Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective
    S V Sorensen
    United BioSource Corporation, Bethesda, Maryland, USA
    Thromb Haemost 105:908-19. 2011
    ..dabigatran etexilate dosing (150 mg bid for patients <80 years, 110 mg bid for patients ≥80 years) versus warfarin and "real-world" prescribing (i.e...
  62. ncbi Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation
    Albert L Waldo
    Division of Cardiology, Case Western University University Hospitals of Cleveland, Cleveland, Ohio 44106 5038, USA
    J Am Coll Cardiol 46:1729-36. 2005
    The purpose of this study was to determine both treatment gaps and predictors of warfarin use in atrial fibrillation (AF) patients enrolled in a national multicenter study.
  63. ncbi Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation
    James V Freeman
    Stanford University School of Medicine, California, USA
    Ann Intern Med 154:1-11. 2011
    b>Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation (AF) but increases the risk for hemorrhage...
  64. ncbi A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
    Giovanna D'Andrea
    Unita di Aterosclerosi e Trombosi, Istituto di Ricovero e Cura a Carattere Scientifico, S Giovanni Rotondo, Foggia, Italy
    Blood 105:645-9. 2005
    Patients require different warfarin dosages to achieve the target therapeutic anticoagulation. The variability is largely genetically determined, and it can be only partly explained by genetic variability in the cytochrome CYP2C9 locus...
  65. ncbi Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese
    Pei Chieng Cha
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    Hum Mol Genet 19:4735-44. 2010
    b>Warfarin is a commonly used anticoagulant, whose dose needs to be determined for each individual patient owing to large inter-individual variability in its therapeutic dose...
  66. ncbi Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am J Cardiol 100:1419-26. 2007
    ..doses of 50-, 150-, or 300-mg dabigatran twice daily alone or combined with 81- or 325-mg aspirin or open-label warfarin administered to achieve an international normalized ratio of 2 to 3 for 12 weeks...
  67. ncbi Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand
    Arch Intern Med 167:239-45. 2007
    b>Warfarin sodium reduces stroke risk in patients with atrial fibrillation, but international normalized ratio (INR) monitoring is required...
  68. ncbi Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
    S Bertil Olsson
    Department of Cardiology, University Hospital, Lund SE 221 85, Sweden
    Lancet 362:1691-8. 2003
    b>Warfarin prevents ischaemic stroke in patients with non-valvular atrial fibrillation, but dose adjustment, coagulation monitoring, and bleeding risk limit its use...
  69. ncbi Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation
    Elaine M Hylek
    Department of Medicine, Boston University School of Medicine, MA 02118, USA
    Stroke 37:1075-80. 2006
    Numerous studies have documented under use of warfarin particularly among elderly patients...
  70. ncbi Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
    David R Holmes
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Lancet 374:534-42. 2009
    ..We assessed the efficacy and safety of percutaneous closure of the LAA for prevention of stroke compared with warfarin treatment in patients with atrial fibrillation.
  71. pmc Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis
    Victoria L Baczek
    Department of Pharmacy Practice, University of Connecticut School of Pharmacy, 69 North Eagleville Road, Storrs, CT 06268, USA
    BMC Fam Pract 13:5. 2012
    Despite warfarin's marked efficacy, not all eligible patients receive it for stroke prevention in AF...
  72. ncbi Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis
    Adeela Nematullah
    University of Toronto, Ontario, Canada
    J Can Dent Assoc 75:41. 2009
    To evaluate the effect of continuing warfarin therapy on the bleeding risk of patients undergoing elective dental surgical procedures.
  73. ncbi Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study
    Leif Friberg
    Karolinska Institute and Department of Cardiology, Danderyd University Hospital, Storskogsvagen 5, Bromma, Stockholm, S 16765, Sweden
    Circulation 125:2298-307. 2012
    ..Our objective was to investigate how to maximize the likelihood of avoiding both stroke and bleeding...
  74. ncbi Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation
    Hiu Ting Chan
    Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, China
    J Cardiovasc Pharmacol 58:87-90. 2011
    It has been established that herbal intake affects the anticoagulation effects of warfarin, but the long-term impact on anticoagulation control is unclear...
  75. ncbi The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
    Elizabeth A Sconce
    School of Clinical and Laboratory Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom
    Blood 106:2329-33. 2005
    Current dosing algorithms do not account for genetic and environmental factors for warfarin dose determinations. This study investigated the contribution of age, CYP2C9 and VKORC1 genotype, and body size to warfarin-dose requirements...
  76. ncbi Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Centre, Amsterdam, Netherlands
    Lancet 379:123-9. 2012
    Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal...
  77. ncbi Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study
    Torben Bjerregaard Larsen
    Department of Cardiology, Cardiovascular Research Centre, Aalborg University Hospital, Aalborg, Denmark
    J Am Coll Cardiol 61:2264-73. 2013
    ..efficacy and safety in an "everyday clinical practice" population of anticoagulant-naïve patients with atrial fibrillation (AF) treated with dabigatran etexilate after its post-approval availability in Denmark, compared with warfarin.
  78. pmc Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
    Antonio de Padua Mansur
    Heart Institute, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
    Clinics (Sao Paulo) 67:543-6. 2012
    ..However, the dosage required to achieve stable anticoagulation remains unknown. The aim of this study was to analyze the warfarin dose necessary for the maintenance of stable oral anticoagulation therapy in elderly patients.
  79. ncbi Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atria
    Stavros Apostolakis
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    J Am Coll Cardiol 60:861-7. 2012
    ..The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation...
  80. ncbi Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial
    Stefan H Hohnloser
    Division of Clinical Electrophysiology, Department of Cardiology, J W Goethe University, Theodor Stern Kai 7, Frankfurt D 60590, Germany
    Eur Heart J 33:2821-30. 2012
    ..Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with warfarin and reduced the rate stroke, death and bleeding in the ARISTOTLE trial...
  81. pmc National trends in oral anticoagulant use in the United States, 2007 to 2011
    Kate Kirley
    Department of Family Medicine, University of Chicago, Chicago, IL, USA
    Circ Cardiovasc Qual Outcomes 5:615-21. 2012
    ..Little is known regarding the adoption of direct thrombin inhibitors in clinical practice. We examine trends in oral anticoagulation for the prevention of thromboembolism in the United States...
  82. ncbi Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States
    William L Baker
    University of Connecticut Hartford Hospital Evidence Based Practice Center, Hartford, CT 06102, USA
    J Manag Care Pharm 15:244-52. 2009
    ..Oral vitamin K antagonists, such as warfarin, can significantly reduce this stroke risk but can be difficult to dose and monitor...
  83. ncbi Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA
    Mattias Wieloch
    Department of Clinical Sciences, Malmo, Lund University, Sweden
    Eur Heart J 32:2282-9. 2011
    In anticoagulation treatment with warfarin, the risk of thrombo-embolic events must be weighed against the risk of bleeding...
  84. ncbi Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation
    Amanda R Harrington
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721 0202, USA
    Stroke 44:1676-81. 2013
    To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin.
  85. ncbi Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years
    Daniela Poli
    Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
    J Am Coll Cardiol 54:999-1002. 2009
    ....
  86. ncbi Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study
    John P Dimarco
    Cardiovascular Division, University of Virginia Health System, Charlottesville, VA 22908, USA
    Am Heart J 149:650-6. 2005
    ..Bleeding is the major complication of anticoagulant treatment, and the relative risks for bleeding vs stroke must be considered when starting anticoagulation...
  87. ncbi Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation
    Catherine J Mercaldi
    United BioSource Corp, 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814, USA
    Stroke 42:112-8. 2011
    in controlled trials, anticoagulation with warfarin reduces stroke risk by nearly two thirds, but the benefit has been less pronounced in clinical practice...
  88. ncbi Use of genetic and nongenetic factors in warfarin dosing algorithms
    Alan H B Wu
    University of California, San Francisco, Department of Laboratory Medicine, Clinical Chemistry Laboratory, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Pharmacogenomics 8:851-61. 2007
    Despite the fact that warfarin has been used as an anticoagulant for many years, the safety profile for this drug has been poor...
  89. ncbi Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis
    Matthew W Reynolds
    MetaWorks Inc, 10 President s Landing, Third Floor, Medford, MA 02155, USA
    Chest 126:1938-45. 2004
    To examine the relationship between international normalized ratio (INR) and outcomes (major bleeding events and strokes) in patients with atrial fibrillation (AF) receiving anticoagulation with warfarin.
  90. ncbi A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study
    Thomas J Wang
    Framingham Heart Study, Framingham, MA 01702 5827, USA
    JAMA 290:1049-56. 2003
    ....
  91. pmc Experimental model of warfarin-associated intracerebral hemorrhage
    Christian Foerch
    Neuroprotection Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Masschusetts 02129, USA
    Stroke 39:3397-404. 2008
    ..As long-term anticoagulation for the prevention of ischemic strokes becomes more prevalent, the burden of warfarin-associated intracerebral hemorrhage (W-ICH) is likely to grow...
  92. ncbi A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
    Hsiang Yu Yuan
    Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
    Hum Mol Genet 14:1745-51. 2005
    b>Warfarin, a commonly prescribed anticoagulant, exhibited large inter-individual and inter-ethnic differences in the dose required for its anticoagulation effect...
  93. ncbi Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, White Oak, Bldg 22, Room 3424, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Arch Intern Med 167:1414-9. 2007
    b>Warfarin sodium is widely used and causes bleeding; a review might suggest the need for regulatory action by the US Food and Drug Administration (FDA).
  94. ncbi Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities
    G P Samsa
    Center for Clinical Health Policy Research, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Arch Intern Med 160:967-73. 2000
    ..Although many studies have addressed the proportion of eligible patients with atrial fibrillation (AF) receiving warfarin sodium, few have addressed the quality of their anticoagulation management.
  95. ncbi A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery
    Karina Meijer
    Division of Haemostasis and Thrombosis, Department of Haematology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
    Thromb Haemost 105:232-8. 2011
    ..This is difficult to achieve, partly because the sensitivity to warfarin decreases progressively during approximately three months after valve surgery...
  96. ncbi The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats
    Nadeem Wajih
    Departments of Internal Medicine and Biochemistry, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    J Biol Chem 279:25276-83. 2004
    ..membrane proteins located in the endoplasmic reticulum membrane and includes the gamma-carboxylase and the warfarin-sensitive enzyme vitamin K(1) 2,3-epoxide reductase (VKOR), which provides gamma-carboxylase with reduced vitamin ..
  97. ncbi Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
    Graeme J Hankey
    Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, Australia
    Lancet Neurol 11:315-22. 2012
    In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF)...
  98. ncbi Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study
    Peter C Block
    Emory University, Atlanta, GA 30322, USA
    JACC Cardiovasc Interv 2:594-600. 2009
    ..The aim of this study was to determine 5-year clinical status for patients treated with percutaneous left atrial appendage transcatheter occlusion with the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) system...
  99. ncbi Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients
    Rina Kimura
    Research Institute, Japan
    Thromb Res 120:181-6. 2007
    The dose required for the anticoagulant effect of warfarin exhibits large inter-individual variations...
  100. ncbi Comparison of two different models of anticoagulation management services with usual medical care
    Kelly M Rudd
    Section of Clinical Pharmacology, Department of Pharmaceutical Care Services, Bassett Medical Center, Cooperstown, New York 13326, USA
    Pharmacotherapy 30:330-8. 2010
    ..To evaluate the safety and economic impact of three models of anticoagulation management services: usual medical care, a nurse-managed service, and a pharmacist-managed service...
  101. ncbi A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)
    Amar Rash
    Northern General Hospital, Medicine for the Elderly, Sheffield, UK
    Age Ageing 36:151-6. 2007
    ..Although trials demonstrate reductions in stroke with warfarin, audit data show that it is still underused. However, anti-coagulation in the very elderly is not without risk.

Research Grants68

  1. Garlic Metabolism and Cytochrome P450 Modulation
    Danny Shen; Fiscal Year: 2007
    ..Adverse interactions between garlic supplements and several narrow therapeutic drugs, including anticoagulants (warfarin, fuindione) and HIV protease inhibitors (saquinavir, ritonavir), have been reported within the past 2 years...
  2. Intralipid: A novel frontline countermeasure for brodifacoum poisoning
    Douglas L Feinstein; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Superwarfarins are modified forms of warfarin (Coumadin) with greater toxicity and longer duration of action...
  3. New Pathways in Thrombosis and Inflammation Mediated by Semaphorin-Plexin Signali
    Guy A Zimmerman; Fiscal Year: 2010
    ..including cyclooxygenase inhibitors (aspirin), thienopyridines (clopidogrel), and anticoagulants (heparin, warfarin)...
  4. Structural and Biochemical Basis of the Vitamin K cycle
    Weikai Li; Fiscal Year: 2013
    ..VKOR is the target of warfarin, the most commonly used oral anticoagulant for treating and preventing thrombosis diseases including deep vein ..
  5. Comprehensive studies of novel SNPs affecting warfarin dose in African Americans
    Minoli Perera; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Warfarin (Coumadin (R)) has been a long-standing target of research because it is both difficult to determine the correct dose and has serious adverse effects...
  6. Deranged Coagulation and Fibrinolytic Cascades in Idiopathic Pulmonary Fibrosis
    MITCHELL ALAN OLMAN; Fiscal Year: 2013
    ..We propose to test this hypothesis by linking to the NHLBI IPFnet clinical research network Warfarin trial (ACE;Anticoagulant Effectiveness in IPF)...
  7. 2012 New Insights into Coagulation
    Eleanor Pollak; Fiscal Year: 2012
    ..hear discussed include the older well-established coagulation agents: heparin and low-molecular weight heparin, warfarin, and intravenous direct thrombin inhibitors...
  8. Development of Headwear To Prevent Fall-Related Injuries in Elderly Persons
    JAMES RIDDELL FERGUSON; Fiscal Year: 2011
    ..mortality from TBI is associated with anticoagulation therapy, including aspirin and the 2 million new users of warfarin each year12...
  9. A multiethnic comparative effectiveness study for diagnosis of cardiogenic stroke
    Jeffrey R Gulcher; Fiscal Year: 2011
    ..The prevention of another stroke due to AF is very different from secondary prevention of other strokes (warfarin vs anti-platelet drugs)...
  10. Dual Use: Safe in Atrial Fibrillation?
    MINANG PRAVIN TURAKHIA; Fiscal Year: 2013
    ..in Atrial Fibrillation: Impact of Mental Illness" (IIR 04- 248), we learned that half of Veterans receiving warfarin in VA actually received INR testing in Medicare (MC) during Fiscal Year 2004 (FY04), suggestion that some ..
  11. VANDERBILT CENTER FOR EDUCATION/RESEARCH ON THERAPEUTICS
    Wayne A Ray; Fiscal Year: 2010
    ..SSRIs and birth defects, 2) ADHD drugs and adverse cardiovascular events, 3) Medications and sudden death, 4) Warfarin and antimicrobial interactions;three are educational programs-5) Improving use of therapy to prevent stroke/..
  12. Human Cytochrome P450 4F Enzymes and Drug Interactions
    ZHUO MICHAEL WANG; Fiscal Year: 2013
    ..been reported between the widely-prescribed cholesterol-lowering agents, the "statins", and the anticoagulant warfarin. Co-administration of these drugs is expected to be on the rise due in part to the purported pleiotropic effects ..
  13. Vitamin K Oxidoreductase: function and physiology
    KATHLEEN LUCILE BERKNER; Fiscal Year: 2012
    ..VKOR, which is the target of anticoagulant drugs like warfarin, becomes inactivated during vitamin K reduction and therefore also requires continuous recycling, which is ..
  14. Risks of Warfarin for Elders with Atrial Fibrillation
    Margaret C Fang; Fiscal Year: 2010
    ..RESEARCH PLAN: The aims of this researchapplication are to (1) determine how advanced age affects warfarin control and poor outcomes from warfarin;(2) assess whether functional decline, fall-risk, and cognitive ..
  15. Axl as a target for the therapy of pancreatic cancer
    Rolf A Brekken; Fiscal Year: 2013
    ..efficacy of inhibiting Gas6 ligand binding to Axl with the clinical vitamin K-dependent carboxylase inhibitor warfarin;2) to characterize the anti-tumor effects of direct inhibition of Axl signal transduction with novel therapeutics...
  16. Predictive optimal anticlotting treatment for segmented patient populations
    Peter J Tonellato; Fiscal Year: 2013
    ..g., warfarin and dabigatran) and antiplatelets (e.g., clopidogrel)...
  17. Arizona Center for Education and Research on Therapeutics
    Raymond L Woosley; Fiscal Year: 2010
    ..centers (CHC) and capture the "teachable moment" when patients are waiting to have blood drawn for monitoring warfarin, digoxin and other drug therapies...
  18. Factors Associated with Warfarin Use in Dialysis Patients w/ Atrial Fibrillation
    JAMES BACON WETMORE; Fiscal Year: 2013
    ..b>Warfarin, a well-studied intervention used to reduce stroke risk in the general population with AF, is considered ..
  19. Risk-Benefit Framework for Genetic Tests
    David L Veenstra; Fiscal Year: 2010
    ..for evaluating the clinical utility of genetic tests in collaboration with stakeholder groups, utilizing warfarin pharmacogenomics as a case example;(2) Assess the generalizability of the framework by applying it to two ..
  20. Structure and Function of the Gamma Carboxylase
    KATHLEEN LUCILE BERKNER; Fiscal Year: 2013
    ..These functions are likely to be affected in the many patients treated with Warfarin, which inhibits carboxylation...
  21. Pharmacogenetics of Warfarin in Puerto Rican Patients using a Physiogenomics Appr
    Jorge Duconge; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Warfarin is a frequently prescribed drug for both the treatment and prevention of thromboembolic complications...
  22. DEVELOPMENT OF A FIRST-IN-CLASS TARGETED FIBRINOLYTIC FOR POST-SURGICAL THROMBOPR
    Ronald Carnemolla; Fiscal Year: 2013
    ..Despite prophylaxis with low molecular weights heparins (LMWHs) or warfarin, 15%-30% patients still develop DVT...
  23. The Pharmacogenomic Control of Clopidogrel Response in Acute Coronary Syndromes
    STUART ALEXANDER SCOTT; Fiscal Year: 2013
    ..His previous pharmacogenetics research centered on the anticoagulant warfarin and the antiplatelet clopidogrel, and he has co-authored clinical pharmacogenetic practice guidelines for both of ..
  24. BRIDGE TRIAL
    Thomas L Ortel; Fiscal Year: 2013
    Description (provided by applicant): Temporary interruption of warfarin therapy for an elective surgical or other invasive procedure is a common clinical problem, affecting ~400,000 patients in North America annually...
  25. BRIDGE TRIAL
    Victor Hasselblad; Fiscal Year: 2013
    Description (provided by applicant): Temporary interruption of warfarin therapy for an elective surgical or other invasive procedure is a common clinical problem, affecting ~400,000 patients in North America annually...
  26. The implementation of a pharmacogenomics-based algorithm for warfarin dosing
    Minoli Perera; Fiscal Year: 2013
    ..b>Warfarin has been a long-standing target of research because of its narrow therapeutic index and serious side effect ..
  27. CHROMATOGRAPHIC AUTOMATION OF IMMUNOASSAYS
    David S Hage; Fiscal Year: 2013
    ..of ultrafast affinity extraction and chromatographic immunoassays, as recently demonstrated for compounds such as warfarin, thyroxine, phenytoin and carbamazepine...
  28. Genetic and Environmental Determinants of Warfarin Response
    Nita A Limdi; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Although the efficacy of warfarin in the treatment and prevention of thromboembolic disorders (TEDs) is proven, it is vastly underutilized with difficulties in management &risk of complications ..
  29. Warfarin vs Aspirin in Reduced Ejection Fraction - STAT
    JOHN L THOMPSON; Fiscal Year: 2010
    ..Its primary aim is to test the primary null hypothesis of no difference between warfarin (INR 2.5-3, target 2...
  30. Personalized medicine informatics for anticoagulation therapy
    Roland Valdes; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Improvements in the safety and efficacy of warfarin therapy will result from intelligent application of knowledge derived from inherited characteristics (CYP2C9 and VKORC1) of individual patients, ..
  31. Comparative effectiveness of dabigatran and warfarin for stroke prevention in atr
    MARY SUSAN VAUGHAN SARRAZIN; Fiscal Year: 2013
    ..The risk of stroke may be lowered with anticoagulation therapy (e.g., warfarin), although the reduction in stroke risk is often accompanied by an increase in the risk of bleeding...
  32. Pharmacogenetics in Rural and Underserved Populations
    Kenneth E Thummel; Fiscal Year: 2013
    ..are already in clinical use, and other promising examples are emerging, including tests to improve the safety of warfarin, tamoxifen and tacrolimus therapy...
  33. GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVT
    Brian F Gage; Fiscal Year: 2013
    ..WarfarinDosing.org) to tailor the dose of warfarin to each person's pharmacogenetic and/or clinical profile...
  34. Prediction of warfarin dosing using clinical and genetic factors
    Stephen E Kimmel; Fiscal Year: 2012
    ..b>Warfarin sodium is the anticoagulant drug of choice to prevent thromboembolism and is prescribed to millions of patients ..
  35. DRUG INTERACTIONS
    ALLAN EDWARD RETTIE; Fiscal Year: 2012
    ..on the magnitude of inhibitory and inductive drug-drug interactions involving the oral anticoagulant drug, warfarin. This information can guide management of warfarin drug interactions in carriers of common polymorphisms within ..
  36. Characterization of Vitamin K Epoxide Reductase
    Darrel W Stafford; Fiscal Year: 2013
    ..VKOR is the target of warfarin, the most widely prescribed anti-coagulant for thromboembolic disorders...
  37. Long Circulating Low Molecular Weight Heparins Pulmonary
    Fakhrul Ahsan; Fiscal Year: 2006
    ..that have traditionally been used for the short and long term treatment of VTE include unfractionated heparin and warfarin. However, treatment of VTE using these traditional drugs has many limitations, including the requirement of ..
  38. Patient-Level Determinants of Oral Anticoagulation Control in the VHA
    Adam J Rose; Fiscal Year: 2013
    ..We will also improve our model by using VA-Medicare data to improve the accuracy of patient race, date of warfarin inception, and hospitalizations...
  39. Chemo-enzymatic Approach to Late-stage Aromatic Fluorination of Drug Scaffolds
    RYAN MARK LAUCHLI; Fiscal Year: 2012
    ..chemical introduction of the aryl fluoride, and 3) to expand the strategy developed in aims 1 and 2 to the drugs warfarin and diclofenac...
  40. Development of a covalent derivative of glycosamino glycans with oral anticoagula
    SIGMUND E LASKER; Fiscal Year: 2010
    ..The use of Coumadin (warfarin) is limited by its very narrow therapeutic index and it's propensity to elicit complications of uncontrolled ..
  41. Venous thromboembolism among California cancer patients
    Helen Chew; Fiscal Year: 2003
    ..This information is important because there is preliminary data suggesting that use of anticoagulants, such as warfarin or low molecular weight heparin, may be beneficial in the primary prevention of VTE among cancer patients...
  42. Molecular Biology of Stroke in Humans
    Frank R Sharp; Fiscal Year: 2013
    ..The gene profiles for cryptogenic stroke will speed delivery of the most appropriate treatments and make further evaluations of the causes of the cryptogenic strokes quicker, less expensive and more successful. ..
  43. 4D Magnetic Resonance Imaging for Atrial Flow Assessment in Atrial Fibrillation
    Jeffrey J Goldberger; Fiscal Year: 2013
    ..Stroke prevention in AF focuses on inhibiting thrombus formation with the use of warfarin in selected high risk patients...
  44. Improving Patient Safety by Reducing Medication Errors
    BRIAN STROM; Fiscal Year: 2005
    ..hospitalizations due to dose-related medication errors among elderly individuals taking specific high-risk drugs (warfarin, phenytoin, and digoxin), using a State-run population-based pharmaceutical benefit program...
  45. Warfarin vs. Aspirin in Reduced Ejection Fraction (WARCEF)
    Shunichi Homma; Fiscal Year: 2010
    ..However, the value of antithrombotic / antiplatelet therapy to reduce adverse events remains controversial. Warfarin and aspirin are most often used without definitive data...
  46. Targeted Antithrombotic Therapy in Cryptogenic Stroke with Patent Foramen Ovale
    David M Kent; Fiscal Year: 2013
    ..For patients with known cardioembolic IS, anticoagulation (AC) (e.g. with warfarin) is the antithrombotic therapy of choice...
  47. Gene Discovery for Warfarin-Related Intracerebral Hemorrhage
    Jonathan Rosand; Fiscal Year: 2012
    Intracerebral hemorrhage (ICH) is the deadliest stroke subtype. Warfarin, a widely used anticoagulant for prevention of thromboembolic stroke, increases both risk and severity of ICH...
  48. Warfarin Use in ESRD Patients with Atrial Fibrillation: Risks, Benefits, Behavior
    WOLFGANG CHRISTOPH WINKELMAYER; Fiscal Year: 2010
    ..In the general population, oral anticoagulation with warfarin reduces this risk substantially, and its benefits have been shown to clearly outweigh an increased bleeding risk...
  49. Cost Effectiveness of Anticoagulation Versus Genetic Testing of CYP2C9 & VKORC1 G
    Anna Teschemaker; Fiscal Year: 2009
    ..The use of genetic testing for the CYP2C9 and VKORC1 genes in order to guide warfarin dosing for patients with VTE holds significant promise potentially to reduce the incidence of over-and under ..
  50. Preventing Gastroduodenal Bleeding in Oral Anticoagulant Users
    Wayne A Ray; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Warfarin is a mainstay of cardiovascular pharmacotherapy and one of the most frequently prescribed medications in the U.S...
  51. Clinical and Genetic Predictors of Unstable Warfarin Response
    BRIAN FINKELMAN; Fiscal Year: 2013
    ..award will consist of two complimentary projects designed to help determine which patients will respond poorly to warfarin therapy in order to provide a rational basis for the clinical decision of when to use newer alternative ..
  52. Development Of Prognostic Platelet RNA Biomarkers To Tailor Antiplatelet Therapy
    Deepak Voora; Fiscal Year: 2013
    ..are expected to have an important positive impact, because analogous to the International Normalized Ratio for warfarin, developing such an assay is a critical step towards a novel treatment paradigm where use of platelet inhibitors ..
  53. A Novel Approach to Assessing Cryptogenic Stroke
    Frank R Sharp; Fiscal Year: 2013
    ..This would prevent thousands of strokes per year and is equivalent to the number of strokes treated with tPA per year. ..
  54. Randomized Clinical Trial of Genotype Guided Dosing of Warfarin Therapy
    STEPHEN KIMEL; Fiscal Year: 2011
    Current dosing practices for warfarin are empiric and result in the need for frequent dose changes as the International Normalized Ratio (INR) gets too high or too low...
  55. Atrial Fibrillation Management and Care Transitions among Nursing Home Residents
    SARAH KATHRYN DUTCHER; Fiscal Year: 2013
    ..with AFIB are at risk for adverse drug events, as pharmacotherapeutic management of AFIB, especially the use of warfarin, can be problematic among older adults...
  56. Method for Prediction of Efficacy of Genetic-Based Prediction Models of Personali
    Peter J Tonellato; Fiscal Year: 2010
    ..a review of the literature demonstrates that at least 35 published algorithms for the prediction of therapeutic warfarin dosing have been published in the past ten years, nine of which include genotype data (unpublished review)...
  57. VITAMIN K AND SKELETAL HEALTH
    Neil Binkley; Fiscal Year: 2000
    ..hypotheses, the overall goal of the proposed research is to determine if vitamin K or the vitamin K antagonist warfarin have a role in determining skeletal health. In this regard, we hypothesize that: 1...
  58. OPTIMAL ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION
    Brian Gage; Fiscal Year: 2001
    ..available data, we will compare outcomes in a cohort of 3600 Medicare beneficiaries with AF who were prescribed warfarin, aspirin, or neither upon hospital discharge...
  59. Improving Anti-Thrombotic Use in Stroke Prevention
    Rebecca Beyth; Fiscal Year: 2006
    ..Evidence from controlled clinical trials shows that adjusted-dose warfarin decreases the risk of stroke by two-thirds...
  60. MRI method for quantitatively mapping cerebral microbleeds
    Yi Wang; Fiscal Year: 2013
    ..4) Apply QSM to measure CMB in warfarin-treated patients with and without ICH...
  61. VITAMIN K-DEPENDENT PROTEINS IN BLOOD AND DEVELOPMENT
    David Roth; Fiscal Year: 2001
    ..b>Warfarin, a potent vitamin K antagonist, is a widely used anticoagulant which indirectly inhibits the activity of the ..
  62. IMPROVING ADHERENCE FOR DYSLIPIDEMIA AND ANTICOAGULATION
    Peter Rudd; Fiscal Year: 2003
    ..and thereby cardiovascular morbidity and mortality, and (2) Chronic oral anticoagulation therapy with warfarin for dysrhythmias, prosthetic heart valves, congestive heart failure, and thromboembolism...
  63. TUMOR PROCOAGULANT;ROLE IN METASTASIS
    MOHAN CHELLADURAI; Fiscal Year: 1993
    ..Induction of thrombocytopenia with antiplatelet antiserum or anticoagulation with warfarin result in inhibition of metastasis...
  64. Randomized Clinical Trial of Genotype Guided Dosing of Warfarin Therapy
    STEPHEN KIMEL; Fiscal Year: 2013
    The objective of the Genotype-Guided Dosing of Warfarin Therapy is to conduct a 1,965 participant randomized, double-blind trial comparing three possible approaches to guiding warfarin therapy initiation: 1) initiation of warfarin therapy ..
  65. SCANNER: Scalable National Network for Effectiveness Research
    Lucila Ohno Machado; Fiscal Year: 2010
    ..prasugrel) and antithrombotic agents (dabigatran) as compared to their standard counterparts clopidogrel and warfarin, respectively...
  66. PHARMACOGENOMICS OF ARRHYTHMIA THERAPY
    Dan M Roden; Fiscal Year: 2013
    ..While AF therapy often includes warfarin anticoagulation whose major complication is bleeding, pharmacogenomic studies of warfarin response to date have ..
  67. Warfarin Pharmacogenetics in Pediatric Patients
    RONALD N contact HINES; Fiscal Year: 2010
    The International Warfarin Pharmacogenetics Consortium recently published the results of their large retrospective study (IWPC, N Engl J Med 360:753-764, 2009)...
  68. METABOLISM OF NONCOLLAGENOUS BONE PROTEINS
    SATORU NISHIMOTO; Fiscal Year: 1992
    ..acid residues in order to bind to the bone mineral phase, as treatment with the vitamin K antagonist warfarin abolishes the delta-carboxylation of BGP and its mineral binding capacity...